Emily S Reisenbichler

11PUBLICATIONS
27CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 22, 2022
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer.

Michal Marczyk, Tao Qing, Tess O'Meara

|Feb 04, 2022
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.

Julia Foldi, Andrea Silber, Emily Reisenbichler

|Sep 08, 2021
Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer.

Saman Farahmand, Aileen I Fernandez, Fahad Shabbir Ahmed

|Jul 04, 2021
Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.

Mieke R Van Bockstal, Aline François, Serdar Altinay

|May 21, 2021
HER-2/neu-positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update.

Lin Wang, Jaya Ruth Asirvatham, Yanlin Ma

|Feb 09, 2021
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.

Julia Foldi, Andrea Silber, Emily Reisenbichler

Pageof 2

Frequent Collaborators

6 joint publications

David L Rimm

3 joint publications

Lajos Pusztai

2 joint publications

Giuseppe Floris

2 joint publications

Stephen Fox